Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104


Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model.

Moore RG, Lange TS, Robinson K, Kim KK, Uzun A, Horan TC, Kawar N, Yano N, Chu SR, Mao Q, Brard L, DePaepe ME, Padbury JF, Arnold LA, Brodsky A, Shen TL, Singh RK.

PLoS One. 2012;7(4):e34443. doi: 10.1371/journal.pone.0034443. Epub 2012 Apr 3.


Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines.

Brard L, Lange TS, Robison K, Kim KK, Ara T, McCallum MM, Arnold LA, Moore RG, Singh RK.

Gynecol Oncol. 2011 Nov;123(2):370-8. doi: 10.1016/j.ygyno.2011.07.002. Epub 2011 Jul 30.


Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.

Stuckey A, Fischer A, Miller DH, Hillenmeyer S, Kim KK, Ritz A, Singh RK, Raphael BJ, Brard L, Brodsky AS.

BMC Cancer. 2011 Jul 22;11:308. doi: 10.1186/1471-2407-11-308.


Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis.

Uddin S, Jehan Z, Ahmed M, Alyan A, Al-Dayel F, Hussain A, Bavi P, Al-Kuraya KS.

Mol Med. 2011;17(7-8):635-45. doi: 10.2119/molmed.2011.00046. Epub 2011 Mar 21.


Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells.

Kumagai T, O'Kelly J, Said JW, Koeffler HP.

J Natl Cancer Inst. 2003 Jun 18;95(12):896-905.


PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models.

Kawar N, Maclaughlan S, Horan TC, Uzun A, Lange TS, Kim KK, Hopson R, Singh AP, Sidhu PS, Glass KA, Shaw S, Padbury JF, Vorsa N, Arnold LA, Moore RG, Brard L, Singh RK.

Genes Cancer. 2013 Nov;4(11-12):524-34. doi: 10.1177/1947601913507575.


Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo.

Zhang X, Liu P, Zhang B, Mao H, Shen L, Ma Y.

Int J Mol Med. 2013 Sep;32(3):623-8. doi: 10.3892/ijmm.2013.1431. Epub 2013 Jul 4.


Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action.

Chen T, Xu Y, Guo H, Liu Y, Hu P, Yang X, Li X, Ge S, Velu SE, Nadkarni DH, Wang W, Zhang R, Wang H.

PLoS One. 2011;6(6):e20729. doi: 10.1371/journal.pone.0020729. Epub 2011 Jun 6.


c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.

Otte A, Rauprich F, von der Ohe J, Yang Y, Kommoss F, Feuerhake F, Hillemanns P, Hass R.

Oncotarget. 2015 Oct 13;6(31):31640-58. doi: 10.18632/oncotarget.5151.


Suppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxyvitamin D3 and its receptor.

Lungchukiet P, Sun Y, Kasiappan R, Quarni W, Nicosia SV, Zhang X, Bai W.

J Steroid Biochem Mol Biol. 2015 Apr;148:138-47. doi: 10.1016/j.jsbmb.2014.11.005. Epub 2014 Nov 6. Review.


1,24(S)-dihydroxyvitamin D2, an endogenous vitamin D2 metabolite, inhibits growth of breast cancer cells and tumors.

Zinser GM, Tribble E, Valrance M, Urben CM, Knutson JC, Mazess RB, Strugnell SA, Welsh J.

Anticancer Res. 2005 Jan-Feb;25(1A):235-41.


Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer.

Wang JY, Swami S, Krishnan AV, Feldman D.

Prostate. 2012 Nov;72(15):1628-37. doi: 10.1002/pros.22516. Epub 2012 Mar 27.


The UVB1 Vitamin D analogue inhibits colorectal carcinoma progression.

Ferronato MJ, Alonso EN, Gandini NA, Fermento ME, Villegas ME, Quevedo MA, Arévalo J, López Romero A, Rivadulla ML, Gómez G, Fall Y, Facchinetti MM, Curino AC.

J Steroid Biochem Mol Biol. 2016 Oct;163:193-205. doi: 10.1016/j.jsbmb.2016.05.019. Epub 2016 May 18.


HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase.

Selvendiran K, Ahmed S, Dayton A, Ravi Y, Kuppusamy ML, Bratasz A, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Mol Cancer Res. 2010 Sep;8(9):1188-97. doi: 10.1158/1541-7786.MCR-10-0201. Epub 2010 Aug 16.


Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.

Yu L, Wang Y, Yao Y, Li W, Lai Q, Li J, Zhou Y, Kang T, Xie Y, Wu Y, Chen X, Yi C, Gou L, Yang J.

Int J Gynecol Cancer. 2014 Sep;24(7):1158-64. doi: 10.1097/IGC.0000000000000179.


The effects of 1alpha,24(S)-dihydroxyvitamin D(2) analog on cancer cell proliferation and cytokine expression.

Shany S, Levy Y, Lahav-Cohen M.

Steroids. 2001 Mar-May;66(3-5):319-25.


Blocking epidermal growth factor receptor activation by 3,3'-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo.

Kandala PK, Wright SE, Srivastava SK.

J Pharmacol Exp Ther. 2012 Apr;341(1):24-32. doi: 10.1124/jpet.111.188706. Epub 2011 Dec 28.


Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium.

Polek TC, Murthy S, Blutt SE, Boehm MF, Zou A, Weigel NL, Allegretto EA.

Prostate. 2001 Nov 1;49(3):224-33.


Effect of a vitamin D(3) derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model.

Lange TS, Stuckey AR, Robison K, Kim KK, Singh RK, Raker CA, Brard L.

Invest New Drugs. 2010 Oct;28(5):543-53. doi: 10.1007/s10637-009-9284-y. Epub 2009 Jul 7.

Supplemental Content

Support Center